Skip to main content
×
Home
    • Aa
    • Aa

Attributable Mortality Rate for Carbapenem-Resistant Klebsiella pneumoniae Bacteremia

  • Abraham Borer (a1), Lisa Saidel-Odes (a2), Klaris Riesenberg (a2), Seada Eskira (a1), Nejama Peled (a3), Ronit Nativ (a1), Francise Schlaeffer (a2) and Michael Sherf (a4)...
Abstract
Objective.

To determine the attributable (direct) mortality and morbidity caused by carbapenem-resistant Klebsiella pneumoniae bacteremia.

Design.

A matched retrospective, historical cohort design, using a stepwise procedure to stringendy match the best control subjects to the best case subjects.

Setting.

A 1,000-bed tertiary-care university teaching hospital.

Patients.

Case subjects were defined as adult patients with carbapenem-resistant K. pneumoniae bacteremia during the period from October 2005 through October 2008. Control subjects were defined as patients who were very similar to case subjects except that they did not have bacteremia.

Methods.

Matching potential control subjects to case subjects was performed at a 1:1 ratio using a computerized record system. The criteria used included same hospitalization period, similar Charlson comorbidity index, same underlying disease, same age within 10 years, and same sex. Demographic and clinical characteristics were collected from medical records.

Results.

During the study period, 319 patients developed an infection due to carbapenem-resistant K. pneumoniae. Of these 319 patients, 39 (12.2%) developed a bloodstream infection, for an overall rate of 0.59 episodes of carbapenem-resistant K. pneumoniae bacteremia per 10,000 patient-days. We excluded 7 patients from our study, leaving a total of 32 case subjects in our cohort. Case subjects were significandy more likely than control subjects (n = 32) to require care in an intensive care unit (12 case subjects [37.5%] vs 3 control subjects [9.4%]), ventilator support (17 case subjects [53.1%] vs 8 control subjects [25%]), and use of a central venous catheter (19 case subjects [59.4%] vs 9 control subjects [28.1%]). For case subjects, the crude mortality rate was 71.9% (ie, 23 of the 32 case subjects died); for control subjects, the crude mortality rate was 21.9% (ie, 7 of the 32 control subjects died) (P < .001. For case subjects, the attributable mortality was 50% (95% confidence interval [CI], 15.3%-98.6%). A mortality risk ratio of 3.3 (95% CI, 2.9-28.5) was found for case subjects with carbapenem-resistant K. pneumoniae bacteremia.

Conclusions.

Patients with carbapenem-resistant K. pneumoniae require more intensive and invasive care. We have shown that the crude and attributable mortality rates associated with carbapenem-resistant K. pneumoniae bacteremia were striking.

Copyright
Corresponding author
Infection Control and Hospital Epidemiology Unit, Soroka University Medical Center, PO Box 151, Beer-Sheva 84101, Israel (borer07@nir.org.il)
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

2. M Schwaber , S Klarfeld-Lidji , S Navon-Venezia , D Schwartz , A Leavitt , Y Carmeli . Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008;52:10281033.

3. Z Samra , O Ofir , Y Lishtzinsky , L Madar-Shapiro , J Bishara . Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel. Int J Antimicrob Agents 2007;30:525529.

, . . ;():–.5. PG Davey C Marwick Appropriate vs. inappropriate antimicrobial therapy Clin Microbiol Infect 2008 14 Suppl 31521

, , , . ;:–.7. ME Falagas PI Rafailidis D Kofteridis et al.Risk factors of carbapenem-resistant infections: a matched case-control studyKlebsiella pneumoniae J Antimicrob Chemother 2007 60 11241130

8. D Pittet , D Tarara , RP Wenzel . Nosocomial bloodstream infection in critically ill Patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1994;271:15981601.

9. MB Edmond , JF Ober , JD Dawson , DL Weinbaum , RP Wenzel . Vanco-mycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996;23:12341239.

10. RP Dellinger , MM Levy , JM Carlet , et al.Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296327.

12. KF Anderson , DR Lonsway , JK Rasheed , et al.Evaluation of methods to identify the Klebsiella pneumoniae carbapenase in enterobactereaceae. J Clin Microbiol 2007;45:27232725.

, , , , , . . ;:–.14. MS Rangel-Frausto D Pittet M Costigan T Hwang CS Davis RP Wenzel The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study JAMA 1995 273 117123

15. O Gudlaugsson , S Gillespie , K Lee , et al.Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003;37:11721177.

16. CD Salgado , BM Farr . Outcomes associated with vancomycin-resis-tant enterococci: a meta-analysis. Infect Control Hosp Epidemiol 2003;24:690698.

, , , , . . ;:–.17. E Senol J Desjardin PC Stark L Barefoot DR Snydman Attributable mortality of bacteremiaStenotrophomonas maltophilia Clin Infect Dis 2002 34 16531656

, , , . . ;:–.18. CM Redondo MDJ Arbo J Grindlinger DR Snydman Attributable mortality of bacteremia associated with the Bacteroides fragilis group Clin Infect Dis 1995 20 14921496

19. MA Martin , MA Pfaller , RP Wenzel . Coagulase-negative staphylococcal bacteremia, mortality and hospital stay. Ann Intern Med 1989;110:916.

20. J Cobo , MI Morosini , V Pintado , et al.Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 B-lactamase-producing Klebsiella pneumoniae epidemic clone. Diagn Microbiol Infect Dis 2008;60:319322.

21. SK Kasiakou , A Michalopoulos , ES Soteriades , G Samonis , GJ Sermaides , ME Falagas . Combination therapy with intravenous Colistin for management of infections due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005;49:31363146.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Infection Control & Hospital Epidemiology
  • ISSN: 0899-823X
  • EISSN: 1559-6834
  • URL: /core/journals/infection-control-and-hospital-epidemiology
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 25 *
Loading metrics...

Abstract views

Total abstract views: 364 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 28th March 2017. This data will be updated every 24 hours.